Mergers & Acquisitions ·
AbbVie Inc. reported second-quarter 2026 financial results with net revenues of $16.99 billion, a 10.2 percent…
ABBVAbbVie Inc.
AbbVie Inc. reported second-quarter 2026 financial results with net revenues of $16.99 billion, a 10.2 percent increase, and adjusted diluted EPS of $3.65, up 22.9 percent. The company announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion to expand its immunology portfolio, with the transaction expected to close in the third quarter of 2026. AbbVie updated its full-year adjusted diluted EPS guidance range downward from $13.91-$14.11 to $13.87-$14.07, reflecting a $0.14 per share dilutive impact from the acquisition and $0.58 in acquired IPR&D expenses. Key product highlights included Skyrizi revenues of $5.5 billion and Rinvoq revenues of $2.5 billion. AbbVie Inc. operates in the pharmaceutical industry, discovering and delivering innovative medicines across immunology, neuroscience, oncology, and aesthetics.